Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208214 | 0.65 | GSK3A (0.30) | GSK3AGSK3B | |
| SCHEMBL2192806 | 0.64 | — | — | |
| SCHEMBL30696109 | 0.62 | — | — | |
| SCHEMBL30874385 | 0.62 | — | — | |
| SCHEMBL426651 | 0.62 | — | — | |
| SCHEMBL31226927 | 0.61 | — | — | |
| SCHEMBL30084894 | 0.61 | — | — | |
| SCHEMBL11769351 | 0.60 | ALOX5 (0.32) | — | |
| SCHEMBL2387226 | 0.60 | — | — | |
| SCHEMBL28829629 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6312927-A | — | — | None | — | — | JP | disclosed |
| WO-2026087399-A1 | 2-(4-PIPERIDYL)-6-(IMIDAZO[1,2-B]PYRIDAZIN-6-YL)THIENO[3,2-B]PYRIDINE DERIVATIVES THAT REDUCE THE PROTEIN LEVEL OF HUNTINGTIN (HTT) FOR THE TREATMENT OF HUNTINGTON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998046570-A1 | SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| JP-H06312927-A | ANGIOTENSIN II ANTAGONISTIC AGENT | TANABE SEIYAKU CO LTD | 1994-11-08 | — | — | JP | disclosed |
| US-4602013-A | 3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE, ANTICONVULSANTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | GSK3A 4411/4885GSK3B 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.